Abstract:INTRODUCTION:In China, efforts to qualify innovative medical products for reimbursement used to be subject to substantial delays after regulatory approval due to fiscal and bureaucratic barriers. In this review, we surveyed the Chinese government's most recent initiatives to improve access to innovative medicines from both the regulatory and the reimbursement aspects, which not only accelerated the launching of drugs in the Chinese market but also expanded the reimbursement coverage of such products. We also provided a discussion of the current challenges.AREAS COVERED:We provided a comprehensive review of the updates in China's national reimbursement listing policies of medicines.EXPERT OPINION:As the most recognized regulatory shortcuts, priority and conditional approvals have expedited the authorization of many innovative medicines. In addition, the national negotiation process was institutionalized to enable timely access to innovative medicines through the National Reimbursement Drug List, leading examples of which were new anticancer drugs. Other impactful reimbursement policies in recent years included dynamic updates of the National Reimbursement Drug List, manufacturer-initiated reimbursement coverage applications, and parallel fund robustness tests and pharmacoeconomic analyses for price estimation. Recent administrative efforts have substantially improved the access to and affordability of innovative medicines in China. Nevertheless, standardized and transparent evidence appraisal processes need to be established for informed decision making in the future.

Comparing the Intellectual Property Financing Policies between China and Japan:A Case Study of Innovative Drugs' Patent-Pledging

Research on Incentive Policies of Innovative Drugs in Japan and Its Enlightenment to China-an Empirical Study on Research and Development of Edaravone

Comparison of Sino-Japanese innovative drug market access policy environment and enlightenment to China

The Comparative Study on Supervision and Incentive Policies of Sino-US During the Innovative Drug R&D

Novel drug research and development ability in China: An international comparison and analysis

The Situation and Strategies of Pledge and Financing with Intellectual Property Rights in Chinese Pharmaceutical Enterprises

International comparison of incentive policies for orphan drug and its enlightenment to China

From Imitation to Innovation: A Study of China's Drug R&D and Relevant National Policies

Study On Chinese Drug Patent Linkage System Druing Approval Process—The Empirical Analysis Based On US and China's Patent Linkage System

Policy Updates on Access to and Affordability of Innovative Medicines in China.

An Overall Analysis of Judicial Protection for Drug Patent in China:Focus on Legislation and Juridical Practice

Quantitative Analysis of Judicial Protection for New Drug R&D in China:A Empirical Study Based on Drug Patent Cases

A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators

Analysis of Biopharmaceutical Innovation Investment in China and Its Policy Causes——On the Basis of the Status Quo of Innovation Investment in United States, Europe and China by Empirical Evaluation

Pledge to green: the green innovation effect of intellectual property pledge financing pilot policy

Method of new patent drug pricing and administration in China

Orphan drug regime in Japan and enlightenment on China: based on evaluation of orphan drug access in Japan

The Risk Compensation Mechanism of Intellectual Property Pledge Financing: American Experience and Enlightenment

Study on The Incentive Policies of Intellectual Property Pledge Financing——Empirical Analysis Based on Beijing's Interest Subsidy Mode

Study on the Value Evaluation of Intellectual Property Pledge Financing

Analysis on the U.S. Intellectual Property Licensing Revenue Pledge Loan Model: Based on the Empirical Study on the High-tech Biomedical Plege Loan of Dyax Corp